Endo Pharmaceuticals has successfully completed the tender offer of $370.0 million by its wholly-\owned subsidiary, BTB Purchaser, for all of the outstanding shares of common stock of Indevus Pharmaceuticals (Marketletter January 12). American Stock Transfer & Trust Co, the depositary for the tender offer, has advised Endo that, as of 5:00 p.m., New York City time, on February 20, the initial expiration of the tender offer, around 61,358,944 shares were validly tendered and not withdrawn, representing around 78% of Indevus' issued and outstanding shares. All validly-tendered shares have been accepted for payment and Endo says it will pay for all of these promptly.
Endo also said that it would make available a subsequent offering period commencing immediately and expiring on February 27 for all Indevus shares not tendered into the offer prior to the initial expiration date. During the subsequent offering period, BTB will accept for payment and promptly pay for Indevus shares as they are tendered. Stockholders who tender shares during such period will receive the same $4.50 per Indevus share in cash and the contractual right to receive up to an additional $3.00 a share in cash payable upon achievement of certain regulatory and sales milestones as was paid to Indevus stockholders pursuant to the tender offer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze